Skip to content

Liposomal Bupivacaine Intercostal Nerve Block Combined with Chest Tube Fixation Strategy for Postoperative Pain Management after VATS: A Multicenter Randomized Controlled Trial

Liposomal Bupivacaine Intercostal Nerve Block Combined with Chest Tube Fixation Strategy for Postoperative Pain Management after VATS: A Multicenter Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600118112
Enrollment
Unknown
Registered
2026-02-02
Start date
2026-02-02
Completion date
Unknown
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Conventional chest tube management:A 22F chest tube will be placed using conventional techniques.
Chest tube internal fixation:A 22F chest tube will be inserted using an intrathoracic fixation technique, with fixation of the intrathoracic end of the tube.

Sponsors

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.American Society of Anesthesiologists (ASA) physical status classification I–III; 2.Age between 20 and 70 years; 3.Undergoing uniportal video-assisted thoracoscopic surgery (VATS); 4.No severe diseases of the heart, brain, lungs, liver, kidneys, or other major organs.

Exclusion criteria

Exclusion criteria: 1. Allergy to local anesthetics; 2.Severe coagulation disorders; 3.Morbid obesity; 4.History of chronic pain; 5.Previous pleural interventions, such as talc pleurodesis, pleurectomy, or chest wall resection; 6.Long-term use or abuse of analgesic or sedative drugs; 7.History of alcohol or drug abuse, or psychiatric disorders; 8.Presence of systemic infectious diseases or recent use of corticosteroids or immunosuppressive therapy; 9.History of prior unilateral lung surgery; 10.Presence of other malignant tumors.

Design outcomes

Primary

MeasureTime frame
Mean Numeric Rating Scale (NRS) pain score within 72 hours after surgery;

Secondary

MeasureTime frame
Time to first press of the patient-controlled analgesia (PCA) pump after surgery;NRS pain scores at rest and during coughing at 24, 48, and 72 hours postoperatively;Incidence of nerve block–related adverse events;Incidence of moderate-to-severe acute postoperative pain at 48 hours after surgery;Number of postoperative rescue analgesia interventions, types of rescue analgesic medications used, and total dosages administered;Incidence of chronic postoperative pain at 3 months after surgery;Incidence of postoperative neuropathic pain at 3 months after surgery;Total sufentanil consumption within 48 h after surgery;Incidence of postoperative nausea and vomiting;Tumor prognosis;

Countries

China

Contacts

Public ContactYan Tao

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

blizzardyt@163.com+86 135 2255 3375

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026